Biotronik Reaches 100,000 DX ICDs Implanted

Biotronik has achieved the milestone of 100,000 implanted single-lead, implantable cardioverter-defibrillators (ICDs) with its DX technology, which allows direct atrial sensing for atrial fibrillation (AFib) detection and monitoring.
 
DX technology is available as a single-lead system and equipped with a floating atrial dipole. According to the company, this provides reliable, timely information about atrial arrhythmias and detects AFib early. After detection, the DX ICD helps monitor AFib burden over time so clinicians can intervene as needed.
 
“Reaching this significant milestone, BIOTRONIK stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful innovations in the market, such as DX Technology, that make a real difference in patients’ lives,” said Dr. Andreas Hecker, president CRM/EP at Biotronik. “This milestone demonstrates our collective efforts and dedication to making a positive difference and helps us define a new standard in patient care.”
 
The company highlighted that over the past decades, over 20 clinical studies enrolling over 4,000 patients confirmed DX technology’s safety and efficacy. The foundation of clinical evidence was recently enriched by the MATRIX study results, the largest clinical evaluation of DX technology to date.
 
“We are deeply grateful for the trust we’ve received from the medical community. We develop solutions to ease physicians’ workloads and improve patient care through holistic and connected approaches. Our innovations are rooted in trustworthy customer relations, feedback and our extensive expertise in cardiac device implants and leads,” said Dr. David Hayes, Biotronik Inc.’s chief medical officer. “With this impressive milestone and the extensive clinical evidence, DX Technology has proven itself, and I am confident that we will reach more milestones such as this in the years to come.”
 
In August 2023, the company completed the first implantation of its Amvia Edge pacemaker at Mount Sinai Medical Center in Miami, Fla.